Adding Ilixadencel Improved Outcomes in Metastatic RCC Adding Ilixadencel Improved Outcomes in Metastatic RCC

Combining intratumoral injections of ilixadencel with sunitinib improved responses in patients with newly diagnosed synchronous metastatic renal cell carcinoma in the phase 2 MERECA trial.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news